+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alopecia Drugs Market by Drug (Anthralin, Antiandrogens, Finasteride), Disease Area (Alopecia Areata, Androgenetic Alopecia, Cicatricial Alopecia), Administration Route, Patient Demographics, Distribution Channel, Gender - Global Forecast 2025-2030- Product Image
Alopecia Drugs Market by Drug (Anthralin, Antiandrogens, Finasteride), Disease Area (Alopecia Areata, Androgenetic Alopecia, Cicatricial Alopecia), Administration Route, Patient Demographics, Distribution Channel, Gender - Global Forecast 2025-2030- Product Image
Sale

Alopecia Drugs Market by Drug (Anthralin, Antiandrogens, Finasteride), Disease Area (Alopecia Areata, Androgenetic Alopecia, Cicatricial Alopecia), Administration Route, Patient Demographics, Distribution Channel, Gender - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 4905045
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Alopecia Drugs Market grew from USD 2.82 billion in 2023 to USD 2.97 billion in 2024. It is expected to continue growing at a CAGR of 5.66%, reaching USD 4.14 billion by 2030.

The current landscape of the alopecia drugs market is marked by an era of dynamic transformation and accelerated innovation. In recent years, significant investments in research and development have driven the launch of breakthrough therapies that address a range of alopecia conditions. The market has witnessed a notable shift from conventional treatments toward more targeted molecular therapies, underpinning the growing demand for precision medicine. While factors such as increasing patient awareness, evolving diagnostic techniques, and a supportive regulatory environment have all contributed to this growth, the sector still faces certain challenges including cost constraints and varying regional access to advanced therapies.

Recent clinical studies and trials have validated the efficacy and safety of many new drug classes. This has instilled greater confidence among clinicians and patients alike. Furthermore, the integration of digital health solutions and robust data management systems has enabled a more personalized approach to treatment, thereby enhancing overall patient outcomes. As a result, stakeholders are now better positioned to align their strategic initiatives with emerging trends, thereby ensuring sustained market growth and improved healthcare delivery in the realm of alopecia. With a comprehensive understanding of both the opportunities and challenges, the market continues to evolve, setting the stage for significant advancements in patient care.

Transformative Shifts in the Alopecia Drugs Market Landscape

Recent developments in the alopecia drugs market have produced transformative shifts that are reshaping the overall healthcare delivery framework. Driven by rapid technological advancements, the sector has embraced emerging treatment modalities that challenge traditional therapeutic approaches. Innovations such as the incorporation of precision medicine and biologic drug therapies have not only enhanced the clinical effectiveness of treatments but also accelerated the approval and adoption processes. Regulatory agencies have increasingly recognized the potential of these new therapies, subsequently paving the way for faster market entry and greater patient access.

The influence of tailored treatment regimens, which are informed by genetic markers and patient-specific data, is significantly altering market dynamics. Enhanced understanding of the disease pathology and the development of novel drug classes, such as JAK inhibitors and fine-tuned immunosuppressants, have driven a notable evolution in clinical practices worldwide. Additionally, emerging trends such as digital diagnostics and telehealth integration further support the rapid dissemination of innovative treatments. This dynamic shift is not only expanding the treatment portfolio available for various forms of alopecia but also reinforcing a patient-centric approach to care, ultimately fostering a more informed and proactive healthcare ecosystem.

Key Segmentation Insights Driving Market Dynamics

A detailed segmentation analysis provides extensive insights into the multifaceted nature of the alopecia drugs market. The classification based on drug type includes segments such as Anthralin, Antiandrogens, Finasteride, Immunosuppressants, JAK Inhibitors, and Minoxidil. Within the Immunosuppressants group, further granularity is achieved by evaluating individual compounds like Azathioprine, Corticosteroids, Cyclosporine, Methotrexate, and Tacrolimus & Pimecrolim. Similarly, the JAK Inhibitors category is deeply explored by assessing agents including Baricitinib, Brepocitinib, Ritlecitinib, Ruxolitinib, and Tofacitinib. This nuanced approach allows market stakeholders to tailor their strategies based on the therapeutic profile and efficacy of specific compounds.

When the market is segmented by disease area, particular attention is paid to conditions such as Alopecia Areata, Androgenetic Alopecia, and Cicatricial Alopecia. More detailed insights are derived from subdivisions within Alopecia Areata, where sub-categories like Alopecia Totalis and Alopecia Universalis indicate varying severity and treatment responses. A segmentation based on the administration route addresses key perspectives associated with oral, parenteral, and topical administrations. Within the topical remedy category, further differentiation into creams, gels, ointments, and solutions & serum underscores the importance of formulation design in treatment effectiveness. Moreover, patient demographics delineate market segmentation into children, geriatric, middle age, and young adults, while distribution channels highlight the roles of hospital pharmacies, online platforms, and retail pharmacies. Finally, a gender-based segmentation into female and male segments allows for a nuanced understanding of market demands, ensuring that tailored approaches address specific patient needs.

Based on Drug, market is studied across Anthralin, Antiandrogens, Finasteride, Immunosuppressants, JAK Inhibitors, and Minoxidil. The Immunosuppressants is further studied across Azathioprine, Corticosteroids, Cyclosporine, Methotrexate, and Tacrolimus & Pimecrolim. The JAK Inhibitors is further studied across Baricitinib, Brepocitinib, Ritlecitinib, Ruxolitinib, and Tofacitinib.

Based on Disease Area, market is studied across Alopecia Areata, Androgenetic Alopecia, and Cicatricial Alopecia. The Alopecia Areata is further studied across Alopecia Totalis and Alopecia Universalis.

Based on Administration Route, market is studied across Oral Administration, Parenteral Administration, and Topical Administration. The Topical Administration is further studied across Creams, Gels, Ointments, and Solutions & Serum.

Based on Patient Demographics, market is studied across Children, Geriatric, Middle Age, and Young Adults.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online, and Retail Pharmacies.

Based on Gender, market is studied across Female and Male.

Regional Trends Shaping the Market

An examination of regional trends reveals that the alopecia drugs market exhibits considerable variation and opportunity across different parts of the globe. In the Americas, the market benefits from robust healthcare infrastructure and a high level of patient awareness, enabling accelerated adoption of advanced treatment paradigms. Meanwhile, the Europe, Middle East & Africa region illustrates a unique interplay between mature healthcare systems and emerging markets, resulting in blended strategies that combine innovation with established clinical practices.

Asia-Pacific continues to be a fast-growing region, spurred by increasing healthcare investments, a surge in patient demand for effective treatments, and rapidly expanding pharmaceutical sectors. Each of these regions features distinct regulatory frameworks and cultural nuances, further influencing the adoption rate of breakthrough therapies. Consequently, a deep understanding of these regional disparities is essential for companies seeking to customize their market approach, optimize resource allocation, and maximize their competitive edge within this evolving landscape.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Shaping Market Innovations

The competitive landscape of the alopecia drugs market is distinctly characterized by the active involvement of leading pharmaceutical and biotechnology companies. Prominent players such as AbbVie Inc. and Aclaris Therapeutics, Inc. are at the forefront of research and development, consistently delivering novel treatment options that target various forms of alopecia. Other major contributors include Almirall S.A and AndroScience Corporation, whose innovative drug formulations have significantly impacted clinical outcomes.

Biosplice Therapeutics, Inc. and Caregen Co. Ltd. are also making strides in developing advanced therapeutic agents, while Cipla Limited. and Dr. Reddy’s Laboratories Ltd. extend robust market presence through their extensive product pipelines. Companies like Eli Lilly and Company, Equillium, Inc., and GlaxoSmithKline PLC, bolster the market with their ongoing research initiatives, providing multiple innovative platforms. The contributions of HCell Inc. and Himalaya Wellness Company further exemplify the creative approaches taken to tackle the challenges of alopecia. Johnson & Johnson Services, Inc., Kintor Pharmaceutical Limited, and Merck & Co., Inc. consistently enhance the scope of available therapies. Novartis AG and Pelage Pharmaceuticals, Inc. are recognized for their strategic acquisitions and partnerships, while Pfizer Inc., Regeneron Pharmaceuticals Inc., and RepliCel Life Sciences Inc. drive innovation through continuous state-of-the-art research efforts. Additionally, Stemson Therapeutics Corporation, Sun Pharmaceutical Industries Ltd, Triple Hair Group Inc., and Vitabiotics Ltd. play critical roles in shaping the overall competitive landscape with their commitment to quality and advanced product development.

The report delves into recent significant developments in the Alopecia Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Aclaris Therapeutics, Inc., Almirall S.A, AndroScience Corporation, Biosplice Therapeutics, Inc., Caregen Co. Ltd., Cipla Limited., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Equillium, Inc., GlaxoSmithKline PLC, HCell Inc., Himalaya Wellness Company, Johnson & Johnson Services, Inc., Kintor Pharmaceutical Limited, Merck & Co., Inc., Novartis AG, Pelage Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., RepliCel Life Sciences Inc., Stemson Therapeutics Corporation, Sun Pharmaceutical Industries Ltd, Triple Hair Group Inc., and Vitabiotics Ltd..

Actionable Recommendations for Industry Leaders

To capitalize on the expanding opportunities in the alopecia drugs market, industry leaders should consider deploying a number of strategic initiatives that align with both current trends and future projections. It is crucial for organizations to continue their investments in robust research and development, particularly in emerging drug classes, while maintaining a flexible operational framework capable of swiftly adapting to regulatory changes and market dynamics. Enhancing cross-functional collaborations, whether through research consortia or strategic partnerships, can further foster innovation and accelerate the translation of breakthrough therapies from the laboratory to the clinic.

Companies are encouraged to deepen their understanding of market segmentation, ensuring that product development and marketing strategies are precisely tailored to the specific needs of diverse patient groups. Emphasis should be placed on developing targeted solution portfolios that leverage insights from drug classification, disease area, administration routes, and demographic profiles. Furthermore, optimizing the distribution network - bridging hospital, online, and retail channels - will be critical in broadening market reach and ensuring effective supply chain management. In parallel, investing in digital health solutions and data analytics can drive improved clinical outcomes and enhance patient engagement, positioning industry leaders as front-runners in both innovation and patient-centric care.

The comprehensive analysis of the alopecia drugs market underscores the significant potential for growth and innovation in the sector. By integrating detailed segmentation insights with an acute understanding of regional trends, the market narrative has transformed into one characterized by continuous innovation and an unwavering focus on patient outcomes. The evolving treatment modalities - from targeted drug classes and innovative administration strategies to tailored patient demographics - illustrate the dynamic interplay of scientific advancements and market demand.

Looking ahead, industry stakeholders are well positioned to harness new opportunities by streamlining research efforts and adopting more agile business models. With companies making concerted efforts to bridge the gap between clinical efficacy and patient accessibility, the industry is poised for further breakthroughs that will redefine therapeutic standards in alopecia care. The interplay of technology, regulatory support, and a consolidated competitive landscape suggests that future market strategies will require proactive adaptation and a commitment to continuous improvement. Overall, the outlook for the alopecia drugs market remains robust, with significant promise for further advancements in both treatment efficacy and patient quality of life.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising occurrence of alopecia conditions across the globe
5.1.1.2. Growing focus on aesthetic appearance and rising disposable incomes
5.1.2. Restraints
5.1.2.1. Potential risk associated with the recall of hair loss medication
5.1.3. Opportunities
5.1.3.1. Rise of telemedicine and online pharmacies for alopecia treatment
5.1.3.2. Advances in genomics and biotechnology to develop personalized treatment options
5.1.4. Challenges
5.1.4.1. Variability in clinical outcomes causing inconsistent consumer satisfaction for alopecia drugs
5.2. Market Segmentation Analysis
5.2.1. Drug: Utilization of JAK inhibitors in alopecia for directly mitigating inflammatory pathways
5.2.2. Disease Area: Increasing prevalence of alopecia areata due to false attacks of the immune system on hair follicles
5.2.3. Administration Route: Use of injectable drugs in alopecia condition for rapid onset of action and high bioavailability
5.2.4. Patient Demographics: Adoption of alopecia drugs in middle age group integrate seamlessly into busy lifestyles
5.2.5. Distribution Channel: Preference for hospital pharmacies for seamless transition from diagnosis to treatment initiation
5.2.6. Gender: Rising demand of alopecia drugs by males to address baldness and hairline recession
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Alopecia Drugs Market, by Drug
6.1. Introduction
6.2. Anthralin
6.3. Antiandrogens
6.4. Finasteride
6.5. Immunosuppressants
6.5.1. Azathioprine
6.5.2. Corticosteroids
6.5.3. Cyclosporine
6.5.4. Methotrexate
6.5.5. Tacrolimus & Pimecrolim
6.6. JAK Inhibitors
6.6.1. Baricitinib
6.6.2. Brepocitinib
6.6.3. Ritlecitinib
6.6.4. Ruxolitinib
6.6.5. Tofacitinib
6.7. Minoxidil
7. Alopecia Drugs Market, by Disease Area
7.1. Introduction
7.2. Alopecia Areata
7.2.1. Alopecia Totalis
7.2.2. Alopecia Universalis
7.3. Androgenetic Alopecia
7.4. Cicatricial Alopecia
8. Alopecia Drugs Market, by Administration Route
8.1. Introduction
8.2. Oral Administration
8.3. Parenteral Administration
8.4. Topical Administration
8.4.1. Creams
8.4.2. Gels
8.4.3. Ointments
8.4.4. Solutions & Serum
9. Alopecia Drugs Market, by Patient Demographics
9.1. Introduction
9.2. Children
9.3. Geriatric
9.4. Middle Age
9.5. Young Adults
10. Alopecia Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online
10.4. Retail Pharmacies
11. Alopecia Drugs Market, by Gender
11.1. Introduction
11.2. Female
11.3. Male
12. Americas Alopecia Drugs Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Alopecia Drugs Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Alopecia Drugs Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.3.1. Triple Hair and Akums joined hands to launch alopecia treatment Therapy-07 in India
15.3.2. Pelage Pharmaceuticals advances in alopecia treatment with phase 2 trial for innovative topical PP405
15.3.3. US Food and Drug Administration approved deuruxolitinib inhibitor for alopecia in adult
15.3.4. Mount Sinai receives a grant to investigate dupilumab for treating alopecia areata
15.3.5. Pelage Pharmaceuticals secures USD 16.75M funding to advance alopecia treatment PP405
15.3.6. Aclaris Therapeutics strengthens patent portfolio with Sun Pharma agreement for alopecia treatments
15.3.7. Pfizer was awarded approval by the FDA for LITFULO for treating severe alopecia
15.3.8. Sun Pharma expands with acquisition of US-based Concert Pharmaceuticals for USD 576 million
15.4. Strategy Analysis & Recommendation
15.4.1. GlaxoSmithKline PLC
15.4.2. Sun Pharmaceutical Industries Ltd
15.4.3. Eli Lilly and Company
15.4.4. Pfizer Inc.
List of Figures
FIGURE 1. ALOPECIA DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ALOPECIA DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ALOPECIA DRUGS MARKET RESEARCH PROCESS
FIGURE 4. ALOPECIA DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL ALOPECIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 17. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2023 VS 2030 (%)
FIGURE 19. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 23. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. ALOPECIA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 29. ALOPECIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ALOPECIA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ALOPECIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ALOPECIA DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ANTHRALIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ANTIANDROGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY TACROLIMUS & PIMECROLIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY BARICITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY BREPOCITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY RITLECITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY RUXOLITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY MINOXIDIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA TOTALIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA UNIVERSALIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ANDROGENETIC ALOPECIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY CICATRICIAL ALOPECIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY SOLUTIONS & SERUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY MIDDLE AGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ALOPECIA DRUGS MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ALOPECIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 85. CANADA ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 86. CANADA ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 87. CANADA ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. CANADA ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 89. CANADA ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 90. CANADA ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 91. CANADA ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. CANADA ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 93. CANADA ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. CANADA ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 95. MEXICO ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 96. MEXICO ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 99. MEXICO ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 100. MEXICO ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 101. MEXICO ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. MEXICO ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. MEXICO ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES ALOPECIA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC ALOPECIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 127. AUSTRALIA ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 137. CHINA ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 138. CHINA ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 139. CHINA ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. CHINA ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 141. CHINA ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 142. CHINA ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. CHINA ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. CHINA ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 145. CHINA ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. CHINA ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 147. INDIA ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 148. INDIA ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 149. INDIA ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 150. INDIA ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 151. INDIA ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 152. INDIA ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 153. INDIA ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. INDIA ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 155. INDIA ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. INDIA ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 157. INDONESIA ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 167. JAPAN ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 168. JAPAN ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 169. JAPAN ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. JAPAN ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 171. JAPAN ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 172. JAPAN ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 173. JAPAN ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. JAPAN ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 175. JAPAN ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. JAPAN ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 177. MALAYSIA ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 182. MALAYSIA ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 183. MALAYSIA ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. MALAYSIA ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 185. MALAYSIA ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. MALAYSIA ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 187. PHILIPPINES ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 192. PHILIPPINES ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 193. PHILIPPINES ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. PHILIPPINES ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 195. PHILIPPINES ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. PHILIPPINES ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 197. SINGAPORE ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 201. SINGAPORE ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 202. SINGAPORE ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 203. SINGAPORE ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SINGAPORE ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 205. SINGAPORE ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. SINGAPORE ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 207. SOUTH KOREA ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 211. SOUTH KOREA ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 212. SOUTH KOREA ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 213. SOUTH KOREA ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. SOUTH KOREA ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 215. SOUTH KOREA ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. SOUTH KOREA ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 217. TAIWAN ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 219. TAIWAN ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 220. TAIWAN ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 221. TAIWAN ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 222. TAIWAN ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 223. TAIWAN ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. TAIWAN ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 225. TAIWAN ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. TAIWAN ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 227. THAILAND ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 228. THAILAND ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 229. THAILAND ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 230. THAILAND ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 231. THAILAND ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 232. THAILAND ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 233. THAILAND ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. THAILAND ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 235. THAILAND ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. THAILAND ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 237. VIETNAM ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 239. VIETNAM ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 240. VIETNAM ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 241. VIETNAM ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 242. VIETNAM ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 243. VIETNAM ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. VIETNAM ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 245. VIETNAM ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. VIETNAM ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ALOPECIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 258. DENMARK ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 259. DENMARK ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 260. DENMARK ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 261. DENMARK ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 262. DENMARK ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 263. DENMARK ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 264. DENMARK ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. DENMARK ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 266. DENMARK ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. DENMARK ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 268. EGYPT ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 269. EGYPT ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 270. EGYPT ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. EGYPT ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 272. EGYPT ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 273. EGYPT ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 274. EGYPT ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. EGYPT ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 276. EGYPT ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. EGYPT ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 278. FINLAND ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 279. FINLAND ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 280. FINLAND ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. FINLAND ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 282. FINLAND ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 283. FINLAND ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 284. FINLAND ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. FINLAND ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 286. FINLAND ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. FINLAND ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 288. FRANCE ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 289. FRANCE ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 290. FRANCE ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 291. FRANCE ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 292. FRANCE ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 293. FRANCE ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 294. FRANCE ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 295. FRANCE ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 296. FRANCE ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. FRANCE ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 298. GERMANY ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 299. GERMANY ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 300. GERMANY ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 301. GERMANY ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 302. GERMANY ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 303. GERMANY ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 304. GERMANY ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. GERMANY ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 306. GERMANY ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. GERMANY ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 308. ISRAEL ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 318. ITALY ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 319. ITALY ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 320. ITALY ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 321. ITALY ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 322. ITALY ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 323. ITALY ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 324. ITALY ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. ITALY ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 326. ITALY ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. ITALY ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 328. NETHERLANDS ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 329. NETHERLANDS ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 330. NETHERLANDS ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 331. NETHERLANDS ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 332. NETHERLANDS ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 333. NETHERLANDS ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 334. NETHERLANDS ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 335. NETHERLANDS ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 336. NETHERLANDS ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 337. NETHERLANDS ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 338. NIGERIA ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 340. NIGERIA ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 341. NIGERIA ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 342. NIGERIA ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 343. NIGERIA ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 344. NIGERIA ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 345. NIGERIA ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 346. NIGERIA ALOPECIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 347. NIGERIA ALOPECIA DRUGS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 348. NORWAY ALOPECIA DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 349. NORWAY ALOPECIA DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 350. NORWAY ALOPECIA DRUGS MARKET SIZE, BY JAK INHIBITORS, 2018-2030 (USD MILLION)
TABLE 351. NORWAY ALOPECIA DRUGS MARKET SIZE, BY DISEASE AREA, 2018-2030 (USD MILLION)
TABLE 352. NORWAY ALOPECIA DRUGS MARKET SIZE, BY ALOPECIA AREATA, 2018-2030 (USD MILLION)
TABLE 353. NORWAY ALOPECIA DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 354. NORWAY ALOPECIA DRUGS MARKET SIZE, BY TOPICAL ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 355. NORWAY ALOPECIA DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 356. NOR

Companies Mentioned

  • AbbVie Inc.
  • Aclaris Therapeutics, Inc.
  • Almirall S.A
  • AndroScience Corporation
  • Biosplice Therapeutics, Inc.
  • Caregen Co. Ltd.
  • Cipla Limited.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Equillium, Inc.
  • GlaxoSmithKline PLC
  • HCell Inc.
  • Himalaya Wellness Company
  • Johnson & Johnson Services, Inc.
  • Kintor Pharmaceutical Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pelage Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • RepliCel Life Sciences Inc.
  • Stemson Therapeutics Corporation
  • Sun Pharmaceutical Industries Ltd
  • Triple Hair Group Inc.
  • Vitabiotics Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMarch 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 2.97 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.14 Billion
Compound Annual Growth Rate5.6%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Alopecia Areata Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Alopecia Areata Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Alopecia Treatment Market Report by Drug Type, Indication, Gender, Route of Administration, Distribution Channel, and Region 2024-2032 - Product Image

Alopecia Treatment Market Report by Drug Type, Indication, Gender, Route of Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 140 Pages
  • Global
From
Alopecia Treatment Market by Disease Type, Route of Administration, Gender, Treatment Option, End User - Global Forecast 2025-2030 - Product Image

Alopecia Treatment Market by Disease Type, Route of Administration, Gender, Treatment Option, End User - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Alopecia Areata Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Alopecia Areata Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 129 Pages
  • Global
From
Alopecia Drugs - Global Strategic Business Report - Product Image

Alopecia Drugs - Global Strategic Business Report

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.